𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of estramustine phosphate (Estracyt®) in patients with metastatic melanoma

✍ Scribed by Jönsson, Per-Ebbe; Ingvar, Christian; Fernö, Måten; Hafström, Larsolof; Rudenstam, Carl-Magnus

Book ID
123347069
Publisher
Elsevier Science
Year
1988
Weight
299 KB
Volume
24
Category
Article
ISSN
0277-5379

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of spirogermanium in pa
A phase II study of spirogermanium in patients with metastatic malignant melanoma
✍ Elizabeth Eisenhauer; Ian Kerr; Audley Bodurtha; Neill Iscoe; Peter McCulloch; K 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 205 KB

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression oc

Oral estramustine and cyclophosphamide i
Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study
✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi